Benitec Biopharma Limited $BNTC Shares Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. increased its stake in shares of Benitec Biopharma Limited (NASDAQ:BNTC) by 92.0% during the 4th quarter, Holdings Channel reports. The fund owned 151,163 shares of the biotechnology company’s stock after purchasing an additional 72,438 shares during the quarter. Simplify Asset Management Inc.’s holdings in Benitec Biopharma were worth $2,036,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in Benitec Biopharma by 44.5% in the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 904 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Benitec Biopharma in the third quarter worth approximately $79,000. JPMorgan Chase & Co. acquired a new stake in shares of Benitec Biopharma in the second quarter worth approximately $80,000. Bank of America Corp DE boosted its stake in shares of Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,587 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Benitec Biopharma in the second quarter worth approximately $93,000. 52.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BNTC has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Benitec Biopharma in a research note on Monday, March 9th. TD Cowen reaffirmed a “buy” rating on shares of Benitec Biopharma in a research note on Monday, March 9th. Evercore began coverage on Benitec Biopharma in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $25.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Monday, April 20th. Finally, Wall Street Zen upgraded Benitec Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.00.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $11.23 on Monday. Benitec Biopharma Limited has a one year low of $9.85 and a one year high of $17.15. The company has a market cap of $385.75 million, a price-to-earnings ratio of -9.85 and a beta of 0.28. The business’s 50 day moving average price is $11.77 and its 200 day moving average price is $12.10.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. On average, analysts predict that Benitec Biopharma Limited will post -1.06 EPS for the current fiscal year.

About Benitec Biopharma

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.